

Meeting with Pfizer

4 November

Delegation [Art.4.1.b] met with Pfizer representatives on 4 Nov [Art.4.1.b]. [Art.4.1.b], reiterated the company's strong support for TTIP, as the company realizes the opportunity to tackle in particular regulatory barriers. He conceded that the priorities of the sector expressed so far have been rather modest (GMP expectations etc.). The purpose of the visit was to inform us of the outcome of a study [Art.4.1.b] which had the task of identifying priority issues in TTIP.

[Not releasable]

He stressed that they had not yet discussed these ideas in Brussels. They were optimistic to have completed the internal coordination in the next two months. They would then also be able to share the study with us.

He thinks that issues like these could also make a real difference in public perception of TTIP; it is not some abstract issue, but if these issues can be resolved, they will have a real impact on patients across the Atlantic. Issues like these could really help raise support for TTIP.

[Not releasable]

Pfizer met with USTR [Art.4.1.b] prior to meeting Delegation. He said he passed the same message there. They will meet with DOS and DOC as well Congressional staff on this visit as well. In Congress, the aim is at this point to start a general dialogue with key Committees. Aside from the trade committees, they are meeting with House Energy and Commerce and Senate Health, as well as Foreign Relations Committees.

[not relevant]

[not relevant]

[Art.4.1.b]